News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Treatment-experienced people
Manufacturer Recalls Alcohol Swab Products Packaged with Fuzeon, Other Meds

The Triad Group alcohol prep pads, which may be contaminated with Bacillus cereus are co-packaged and distributed with some medications used by people living with HIV, including Genentech's Fuzeon (enfuvirtide) and Pegasys (pegylated interferon, used to treat chronic hepatitis C virus infection).

Published
20 January 2011
From
AIDSmeds
Hepatitis C symptoms and diagnosis
New drugs take aim at hepatitis C, spur debate on whether to test baby boomers

Surprisingly, two-thirds of hepatitis C sufferers are thought to be baby boomers who've harboured since their younger, perhaps wilder, years a virus that can take two or three decades to do its damage.

Published
18 January 2011
From
Canadian Press
Hepatitis C treatment
Bristol-Myers Squibb and Pharmasset Enter into a Clinical Collaboration Agreement for Proof of Concept Combination Study in Patients Chronically Infected with Hepatitis C

Bristol Myers Squibb and Pharmasset announced today that the companies have entered into a clinical collaboration agreement to evaluate the utility of BMS-790052, Bristol-Myers Squibb’s NS5A replication complex inhibitor, in combination with PSI-7977, Pharmasset’s nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus (HCV).

Published
10 January 2011
From
Business Wire
Peregrine Initiates Randomized Phase II Trial of Bavituximab in Chronic Hepatitis C

Peregrine Pharmaceuticals announces open-label trial evaluating 12 weeks of therapy with novel targeted antibody bavituximab in combination with ribavirin versus standard of care.

Published
10 January 2011
From
Market Wire
Hepatitis C treatment
Merck Beats Vertex to FDA Hep C Filing

In the race to market the first next-generation treatment for hepatitis C, Merck is out to an early lead.

Published
07 January 2011
From
The Street
Hepatitis C treatment
Pharmasset Reports Positive Results from its HCV Clinical Programs

Pharmasset, Inc. announced today positive data from interim analyses of two of its clinical programs: the HCV genotype 2 or 3 (GT2/3) arm of the PSI-7977 Phase 2b trial and the 14 day PSI-938 monotherapy cohort of the dual nucleotide study. 

Published
06 January 2011
From
Pharmasset
Hepatitis C treatment
Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients

Anadys Pharmaceuticals, Inc. announced today that it has initiated the planned Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin.

Published
05 January 2011
From
PR Newswire
Hepatitis C treatment
Hepatitis Experts Create Roadmap for Accelerating the Development of Targeted Therapies for Hepatitis C Virus

To improve the care for individuals infected with the hepatitis C virus, a major health problem and a leading cause of chronic liver disease around the world, nearly 200 international hepatitis experts have taken an important step in escalating the introduction of a new class oftargeted therapies for HCV - direct-acting antivirals (DAAs).

Published
15 December 2010
From
Forum for Collaborative HIV Research
Hepatitis C treatment
European recommendations issued on acute hepatitis C infection in patients with HIV

European investigators and activists have developed recommendations for the management of acute hepatitis C infection in patients with HIV. Published in the online edition of AIDS, they cover

Published
15 December 2010
By
Michael Carter
Hepatitis C treatment
Medivir AB reports positive interim data on Phase 2b ASPIRE study for hepatitis C

The results demonstrate the potent and consistent antiviral efficacy of TMC435 in patients who had failed earlier treatment with peg-IFN and ribavarin (standard of care).

Published
18 November 2010
From
Medical News Today
← Prev1...100101102103104...106Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.